Blinklab (ASX:BB1)
We spoke to Henk-Jan Boele, CEO of Blinklab (ASX:BB1), about the company’s roadmap to FDA approval and the subsequent commercial roll out.
Because Blinklab is filing for FDA 510(k) clearance, this roadmap should be a lot shorter than for your typical life sciences company.
Looking for the Best ASX Life Sciences Stocks to invest in right now?
